Medicine and Dentistry
Systematic Review
100%
Human Immunodeficiency Virus
100%
Racial Disparity
50%
Infection
50%
Ethnic Disparity
50%
Awareness
50%
COVID-19
50%
Pre-Exposure Prophylaxis
50%
Human Immunodeficiency Virus Infection
50%
Drug Use
50%
Telemedicine
50%
Hepatitis C Virus
50%
Hepatitis C Treatment
50%
Clinician
43%
Severe Acute Respiratory Syndrome Coronavirus 2
37%
Placebo
28%
Men Who Have Sex with Men
26%
Infection Rate
25%
Health Care
25%
Case Fatality Rate
25%
Ethnic Group
25%
White Population
25%
Ecological Study
25%
Diagnostic Accuracy
21%
Cabotegravir
14%
Randomized Clinical Trial
14%
Emtricitabine
14%
English (Language)
12%
Observational Study
12%
Mortality Rate
12%
Cross Sectional Study
12%
Outcome Assessment
12%
Hospital Mortality
12%
Disease
12%
Selection Bias
12%
Random Effects Model
7%
Tenofovir Disoproxil
7%
Population
7%
Tenofovir Alafenamide
7%
Transgender
7%
Group Frequency
6%
Experimental Therapy
6%
Hepatitis C
6%
Gene Linkage
6%
Study Participant
6%
Medication Compliance
6%
Medicaid Managed Care
6%
Peer Group
6%
Transactional Sex
5%
Health Survey
5%
Keyphrases
People Who Inject Drugs
100%
Hospitalization
59%
Pre-exposure Prophylaxis (PrEP)
50%
Portland Oregon
50%
Racial Disparities
50%
COVID-19
50%
AIDS/HIV
50%
Response Preparation
50%
Startling Acoustic Stimulus
50%
Psychological Refractory Period
50%
Peer Assistance
50%
State Opioid Response
50%
Hepatitis C Virus
50%
Serious Bacterial Infection
50%
Syndemic
50%
Injection Equipment Sharing
32%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
25%
Ecological Study
16%
Hispanic Population
16%
African American
16%
Race-ethnicity
16%
Black Population
16%
Access to Care
16%
White Population
16%
Healthcare Exposure
16%
Non-Hispanic White
16%
Racial-ethnic Groups
16%
Infection Rate
16%
Lower Limb Strength
16%
Dual-task Processing
16%
Infectious Diseases
16%
Prevalence Ratio
13%
Fentanyl
13%
Hepatitis C Virus Infection
9%
Hepatitis C Virus Antibodies
9%
Confidence Interval
9%
Ecological Data
8%
Quality Assessment
8%
Scopus
8%
Exposure Risk
8%
Outcome Assessment
8%
Research Laboratories
8%
CINAHL
8%
Case Fatality Rate
8%
Mortality Rate
8%
Centers for Disease Control
8%
Fatality
8%
Comorbid Conditions
8%
Disease Prevention
8%
Cochrane Central Register of Controlled Trials
8%
